Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4Lymphoid 1Breast 1

Conditions

Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 6Lymphoma 5Multiple Myeloma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Mantle-Cell 3Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Hematologic Neoplasms 2Endometrial Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Ovarian Neoplasms 1Osteosarcoma 1

Interventions

Cyclophosphamide 35Rituximab 33venetoclax 24ibrutinib 14Vincristine 14Prednisone 14Doxorubicin 14Gemcitabine 13pembrolizumab 12fludarabine 12Bendamustine Hydrochloride 11Etoposide 10obinutuzumab 9Filgrastim 9Dexamethasone 9Bortezomib 9fludarabine phosphate 8Mycophenolic Acid 8Drug Therapy 8ofatumumab 7Whole-Body Irradiation 7Sirolimus 7Peripheral Blood Stem Cell Transplantation 7Methotrexate 7Busulfan 7Therapeutics 6Radiotherapy 6Mesna 6Lenalidomide 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × copanlisib × Lymphoid × Clear all
NCT03474744 2026-05-06

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

University of Ulm

Phase 2 Active not recruiting
36 enrolled
Lymphoid

Neoplasms, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡